Simultaneous vaccination against hepatitis A and B: results of a controlled study

Ambrosch, F; André, Francis; Delem, A.; D'Hondt, E.; Jonas, S.; Kunz, C; Safary, Assad; Wiedermann, G

doi:10.1016/0264-410x(92)90570-a

Cited by 54 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No impairment in the expected protective efficacy was noted when HBV was administered with: BCG and IPV,4diphtheria-tetanus (DT) and diphtheria-tetanus-pertussis (DTP),22 OPV,22-24 group A meningococcus vaccine,25 measles vaccine,26 Japanese B encephalitis vaccine,26 and hepatitis A vaccine 2728 Our study is the first to investigate early simultaneous HBV and IPV vaccination in preterm infants.…”

Section: Discussionmentioning

confidence: 87%

Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth

Linder

Handsher²,

German³

et al. 2000

Archives of Disease in Childhood - Fetal and Neonatal Edition

View full text Add to dashboard Cite

Aim-The study was conducted to evaluate the immunogenicity of an early, extra dose of enhanced inactivated poliovirus vaccine (IPV) administered simultaneously with recombinant hepatitis B vaccine (HBV) to preterm infants shortly after birth. Methods-Three groups were studied. Fifty preterm infants received IPV intramuscularly within 24 hours of birth, in addition to routine recommended childhood immunisations. Fifty two preterm infants and 35 full term infants received routine immunisations only (routine vaccination timing: HBV at birth, 1 and 6 months of age; IPV at 2 and 4 months; oral polio vaccine (OPV) at 4 and 6 months; diphtheria-tetanus-pertussis (DTP) at 2, 4, and 6 months; and Haemophilus influenzae B vaccine at 2 and 4 months). Blood samples were taken at birth, 3 and 7 months of age from all infants, and at 1 month of age from preterm infants only. Results-At birth, a lower percentage of both study and control preterm infants had antipoliovirus type 3 titres > 1:8 than full term infants. At 1 and 3 months of age significantly more early IPV infants had antipoliovirus type 3 titres > 1:8 than routinely vaccinated preterm infants (p < 0.05). At 7 months of age there were no significant diVerences in percentage of antipoliovirus titres > 1:8 or geometric mean times (GMTs) between the early IPV group and the routinely vaccinated preterm group. At 3 and 7 months of age, the percentage of positive antihepatitis B titres (> 1:10) and the GMT of the early IPV preterm group did not diVer significantly from those of preterm controls. There was no significant diVerence in percentage of positive antihepatitis B titres between the early IPV group and full term controls at any time. GMTs for hepatitis B antibodies were significantly lower in the early IPV preterm group than in full term controls at 3 and 7 months of age. Conclusions-Administration of an additional dose of IPV simultaneously with routine HBV to preterm infants shortly after birth provides early protection from poliovirus and hepatitis B infection, and does not interfere with poliovirus antibody production at the age of 7 months.

show abstract

Section: Discussionmentioning

confidence: 87%

Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth

Linder

Handsher²,

German³

et al. 2000

Archives of Disease in Childhood - Fetal and Neonatal Edition

View full text Add to dashboard Cite

show abstract

“…After completion of the 3-dose Twinrix series, immunogenicity to hepatitis A and B is equivalent to immunogenicity of people who received single-antigen vaccines administered separately according to standard schedules. 52 Immunogenicity Within 1 month of receiving a first dose of hepatitis A vaccine, 97% of children and adolescents and 95% of adults developed protective concentrations of antibody, with the second dose resulting in virtually 100% of individuals being protected against the infection. 53 Although data are limited, the vaccine is less immunogenic in patients with chronic liver disease, immunocompromised people, transplant recipients, and elderly individuals.…”

Section: Descriptionmentioning

confidence: 99%

Hepatitis A Vaccine Recommendations

2007

Pediatrics

View full text Add to dashboard Cite

Since licensure in 1995 of a hepatitis A vaccine, the Centers for Disease Control and Prevention and the American Academy of Pediatrics have been implementing an incremental hepatitis A immunization strategy for children. In 1996, children living in populations with the highest rates of disease were targeted for immunization, and in 1999 the program was expanded to immunization of children 2 years and older living in states and counties with rates of hepatitis A that historically have been higher than the national average. The 1999 program has been successful; the current rate of hepatitis A is the lowest ever reported in the United States. Regional, ethnic, and racial differences in the incidence of hepatitis A have been eliminated. The incidence of hepatitis A in adults in immunizing states has decreased significantly, suggesting a strong herd-immunity effect associated with immunization. In 2005, the US Food and Drug Administration changed the youngest approved age of administration of hepatitis A vaccine from 24 to 12 months of age, which facilitated incorporation of the vaccine into the recommended childhood immunization schedule. As the next step in the implementation of the incremental vaccine immunization strategy, the American Academy of Pediatrics now recommends routine administration of a Food and Drug Administration-licensed hepatitis A vaccine to all children 12 to 23 months of age in all states according to a Centers for Disease Control and Prevention-approved immunization schedule. Available data suggest that hepatitis A vaccine can be coadministered with other childhood vaccines without decreasing immunogenicity. Hepatitis A vaccines have proven to be extremely safe. In prelicensure clinical trials of both Havrix (GlaxoSmithKline, Rixensart, Belgium) and Vaqta (Merck & Co Inc, Whitehouse Station, NJ), adverse events were uncommon and mild when they occurred, with resolution typically in less than 1 day. Hepatitis A vaccine is contraindicated in people with a history of severe allergic reaction to a previous dose of hepatitis A vaccine or to a vaccine component. Because the hepatitis A vaccine is an inactivated product, no special precautions are needed for administration to people who are immunocompromised. No data exist about administration of the hepatitis A vaccine to pregnant women, but because it is not a live vaccine, the risk to mother and fetus should be extremely low to nonexistent. BACKGROUND AND RATIONALE FOR RECOMMENDATIONSThe purpose of this statement is to provide the rationale and recommendations for universal administration of hepatitis A vaccine to children living in the United States. The rationale for implementation of universal immunization is based on several considerations. For the 15 years before availability of hepatitis A vaccines www.pediatrics.org/cgi

show abstract

“…Nevertheless, the rate of seroconversion appears to be similar. [55] Simultaneous administration of vaccines against hepatitis B [43,[60][61][62] or yellow fever [63] with hepatitis A vaccine resulted in anti-HAY seroconversion rates similar to those seen with hepatitis A vaccine alone. However, in a study involving 51 volunteers who received hepatitis A vaccine 720EU at 0, 1 and 6 months, 49 who received vaccine plus immunoglobulin 700IU, and 49 who received only immunoglobulin, the seroconversion rate was similar after the first month in all groups ( fig.…”

Section: Coadministration With Passive Immunisation or Other Vaccinesmentioning

confidence: 99%

Inactivated Hepatitis A Vaccine (HM175 Strain)

Wagstaff¹,

Plosker²,

Balfour³

1996

Clin. Immunother.

View full text Add to dashboard Cite

Simultaneous vaccination against hepatitis A and B: results of a controlled study

Cited by 54 publications

References 5 publications

Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth

Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth

Hepatitis A Vaccine Recommendations

Inactivated Hepatitis A Vaccine (HM175 Strain)

Contact Info

Product

Resources

About